US Hemp Roundtable Analysis Of FDA CBD Report To Congress

US Hemp Roundtable Analysis Of FDA CBD Report To Congress

More than a week after a Congressional deadline, FDA finally released its long-awaited report to Congress on the potential regulatory pathways for the sale of hemp-derived CBD products. There’s not much cause for celebration — FDA continues to kick the can down the road, claiming that more study is needed before it takes action. The agency’s delay results in the worst of both worlds — U.S. hemp farmers are denied profitable markets for their crops, while unregulated products continue to proliferate, with no safeguards for public health and safety. The report, however, does provide valuable insight into the Agency’s thinking and next steps including the following: FDA is actively evaluating a potential rulemaking to allow CBD in dietary supplements. In the meantime, the agency is considering the issuance of a risk-based enforcement discretion policy to provide more transparency regarding its enforcement priorities.   With regard to adding CBD to food and beverages, FDA maintains that the data currently available raises safety concerns and encourages parties to share relevant information with FDA.   FDA argues that those marketing cosmetics should ensure the safety of their products, noting that there is limited data on topical use of CBD, and that topical products – including those with CBD – should not make structure/function or therapeutic (drug) claims.   FDA is re-opening the docket to obtain information on “full spectrum” and “broad spectrum” hemp extracts, and how they compare to CBD isolate products. The agency is also actively working to develop a sampling study…

Excerpt only …
READ MORE BELOW
Source : CANNANNEW REPORT
Link to original : US Hemp Roundtable Analysis Of FDA CBD Report To Congress
reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.